Skip to main content
TipRanks
Go Ultimate75% OFF

Cuprina Holdings (Cayman) Limited Class A (CUPR) AI Stock Analysis

52 Followers
CUPR

Cuprina Holdings (Cayman) Limited Class A

(NASDAQ:CUPR)

Select Model
Rating:40Underperform
Price Target:$1.50â–²(6.38% Upside)
Action:reiterated
Date:11/06/26

The overall score of 40 reflects a high-risk, development-stage company with severe financial challenges. The most significant factor is the extremely weak financial performance, characterized by accelerating cash burn, negative gross margins, and no clear path to profitability. Technical trends reinforce this weakness, with the stock in a clear downtrend below all major moving averages. The negative P/E ratio further confirms the lack of earnings power. The only positive signal is a recently improved balance sheet, but this is insufficient to offset the overwhelming operational and market headwinds.

Positive Factors
Low absolute leverageModest absolute debt gives Cuprina some financial flexibility compared with a highly leveraged company. This can reduce near-term solvency pressure and leave more capacity to direct capital toward operations, acquisitions, or product development while the business works toward profitability.
Negative Factors
Persistent cash burnConsistently negative operating and free cash flow means Cuprina is not funding its activities internally. The sharp deterioration in 2025 increases dependence on external capital, limits strategic flexibility, and raises execution risk if investment needs remain elevated before operations become self-funding.

Cuprina Holdings (Cayman) Limited Class A (CUPR) vs. SPDR S&P 500 ETF (SPY)

-75%-50%-25%0%25%50%75%CUPR-73.57%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$4.02M
Dividend Yield
―
Average Volume (3M)
115.81K
Price to Earnings (P/E)
-1.0
Beta (1Y)
1.02
Revenue Growth
6.30%
EPS Growth
-208.64%
Country
US
Employees
10
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

Cuprina Holdings (Cayman) Limited Class A Business Overview & Revenue Model

Company Description

Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its fla...

Cuprina Holdings (Cayman) Limited Class A Financial Statement Overview

Summary

Financial performance is critically weak. The income statement reveals minimal, volatile revenue with negative gross margins and widening operating losses. Cash flow is deeply negative, with operating cash burn accelerating to -$9.13M in 2025. The only mitigating factor is a recently strengthened balance sheet from an equity raise, which provides a temporary liquidity cushion but does not offset the severe operational cash consumption.

Income Statement

10Very Negative

Balance Sheet

55Neutral

Cash Flow

8Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue63.24K49.89K48.32K100.77K56.60K58.50K
Gross Profit-16.63K-645-3,02436.60K19.98K23.06K
EBITDA-6.19M-4.56M-1.43M-994.12K-1.06M-489.44K
Net Income-6.01M-4.67M-1.56M-1.12M-1.09M-519.69K
Balance Sheet
Total Assets8.50M8.50M1.75M1.59M1.44M953.05K
Cash, Cash Equivalents and Short-Term Investments3.12M3.12M116.47K35.26K564.58K767.29K
Total Debt482.72K482.72K254.79K121.82K183.63K170.03K
Total Liabilities3.45M3.45M6.20M4.48M3.21M1.64M
Stockholders Equity5.06M5.06M-4.46M-2.90M-1.78M-683.52K
Cash Flow
Free Cash Flow-16.46M-9.19M-1.26M-1.61M-1.87M-224.72K
Operating Cash Flow-16.37M-9.13M-1.24M-1.54M-1.85M-221.86K
Investing Cash Flow-87.19K-58.23K-21.88K-67.98K-31.28K-2,860
Financing Cash Flow21.04M12.23M1.34M1.08M1.68M991.39K

Cuprina Holdings (Cayman) Limited Class A Technical Analysis

Technical Analysis SentimentNegative
Last Price1.41

Price Trends

50DMA1.96Negative
100DMA2.75Negative
200DMA2.89Negative

Market Momentum

MACD-0.12Positive
RSI32.41Neutral
STOCH10.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CUPR, the sentiment is Negative. The current price of 1.41 is below the 20-day moving average (MA) of 1.77, below the 50-day MA of 1.96, and below the 200-day MA of 2.89, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 32.41 is Neutral, neither overbought nor oversold. The STOCH value of 10.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CUPR.

Cuprina Holdings (Cayman) Limited Class A Risk Analysis

Cuprina Holdings (Cayman) Limited Class A disclosed 69 risk factors in its most recent earnings report. Cuprina Holdings (Cayman) Limited Class A reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Cuprina Holdings (Cayman) Limited Class A Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CUPR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CLDICLDI43Neutral$1.74M-0.02-474.66%――85.56%
GOVXGOVX40Underperform$1.04M-0.01-1010.79%―-100.00%-448.40%
CUPRCUPR40Underperform$8.84M-0.95-84.78%―6.30%-208.64%
HCWBHCWB38Underperform$2.31M-0.03-63.04%―1502.05%77.12%

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%CUPRGOVXHCWBCLDIPBMASBPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CUPR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CUPRCuprina Holdings (Cayman) Limited Class A1.41-4.10-74.43%
GOVXGeovax Labs, Inc.1.81-226.19-99.21%
HCWBHcw Biologics, Inc.0.75-12.27-94.25%
CLDICalidi Biotherapeutics, Inc.0.48-20.96-97.78%
PBMPsyence Biomedical Ltd.2.97-6.47-68.53%
ASBPAspire Biopharma Holdings, Inc.7.13-112.87-94.06%

Cuprina Holdings (Cayman) Limited Class A Corporate Events

Cuprina Holdings Shareholders Approve Major Capital Increase and Governance Changes

Oct 20, 2026

Cuprina Holdings (Cayman) Limited reported that on October 15, 2026, shareholders at an extraordinary general meeting in Singapore and via webcast approved a major increase in the company’s authorised share capital from US$100,000 to US$10,000,000, e...

Cuprina Holdings to Acquire Profitable Singapore Podiatry and Women’s Health Clinic Group

Oct 2, 2026

On October 1, 2026, Cuprina’s wholly owned BVI subsidiary signed agreements to acquire all shares of East Coast Podiatry Centre and Orchard Clinic Management for about S$4.0 million, via a mix of cash and Class A shares subject to lock-ups. Completio...

Cuprina Holdings Closes Over-Allotment Option, Lifts Public Offering Proceeds to $5.7 Million

Sep 29, 2026

On September 29, 2026, Cuprina Holdings (Cayman) Limited closed the sale of 648,373 additional Class A ordinary shares at $1.15 per share, following the full exercise of the underwriter’s over-allotment option tied to its recent Nasdaq public offerin...

Cuprina Holdings Calls October EGM to Approve Major Share Capital Increase and Governance Changes

Sep 18, 2026

On September 18, 2026, Cuprina Holdings (Cayman) Limited filed a Form 6-K with the U.S. SEC announcing an extraordinary general meeting of shareholders scheduled for October 15, 2026 in Singapore and via webcast. Shareholders of record as of Septembe...

Cuprina Holdings Raises $4.97 Million in September Nasdaq Offering

Sep 18, 2026

On September 15, 2026, Cuprina Holdings (Cayman) Limited entered into an underwriting agreement with R. F. Lafferty & Co., Inc. for a Nasdaq-listed public offering of 4,322,489 Class A ordinary shares at $1.15 per share, raising gross proceeds of app...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026